

## References

S-208

1. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in Oncology: Non-Hodgkin's lymphoma. v.4.2020.
2. Mussetti A, Devlin SM, et al. Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: A single-center analysis in the rituximab era. *Bone Marrow Transplantation*. 2015;50:1293-1298.
3. National Guideline Clearinghouse (NGC). Non-Hodgkin's lymphoma: diagnosis and management. 2016.
4. National Cancer Institute. Adult Non-Hodgkin Lymphoma Treatment (PDQ®)– Health Professional Version. 2019.
5. Costa L, Kumar S, Stowell S, Dermer J. Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-hodgkin lymphoma. *Cancer Control*. 2015;22:87-94.
6. Valtola J, Varmavuo V, Ropponen A, Selander T, et al. Early immune recovery after autologous transplantation in non-Hodgkin lymphoma patients: predictive factors and clinical significance. *Leukemia and Lymphoma*. 2016;57(9):2025-2032.
7. Hayes, Inc. Hayes Medical Technology Directory Report. *Umbilical Cord Blood Stem Cell Transplantation for Hematological and Lymphoid Malignancies in Adults*. Lansdale, PA: Hayes, Inc.; December, 2017.
8. Picleanu A, Novella S, Monter A, Garcia-Cadenas I, et al. Allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomas: a retrospective analysis of 77 cases. *Ann Hematol*. 2017;96:787-796.
9. Gilli S, Novak U, Taleghani M, Baerlocher G, et al. BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients. *Ann Hematol*. 2017;96:421-429.
10. Gupta A, Gokarn A, Rajamanickam D, Punatar S, Thippeswamy R, Mathew L, et al. Lomustine, cytarabine, cyclophosphamide, etoposide – An effective conditioning regimen in autologous hematopoietic stem cell transplant for

primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors. *J Cancer Res Ther.* 2018;14(5):926-933.

11. Schmitz N, Lenz G, Stelljes M. Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. *Blood.* 2018;132(3):245-253.
12. Schmitz N, Lenz G, Stelljes M. Sarcopenia is associated with autologous transplant-related outcomes in patients with lymphoma. *Leukemia & Lymphoma.* 2015;56(10):2855–2862.
13. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood.* 2016;127(20):2375-2390.
14. Bozkaya Y, Uncu D, Dağdaş S, et al. Evaluation of lymphoma patients receiving high-dose therapy and autologous stem cell transplantation: Experience of a single center. *Indian J Hematol Blood Transfus.* 2017;33(3):361-369.
15. Jiménez-Ubieto A, Grande C, Caballero D, et al. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment. *Hematol Oncol.* 2018;36(5):765-772.
16. Strüßmann T, Fritsch K, Baumgarten A, et al. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation. *Br J Haematol.* 2017;178(6):927-935.
17. Casasnovas RO, Ysebaert L, Thieblemont C, et al. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. *Blood.* 2017;130(11):1315-1326.
18. Qualls D, Sullivan A, Li S, et al. High-dose thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation as upfront consolidation for systemic non-hodgkin lymphoma with synchronous central nervous system involvement. *Clin Lymphoma Myeloma Leuk.* 2017;17(12):884-888.
19. Fujita N, Kobayashi R, Atsuta Y, et al. Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma. *Int J Hematol.* 2019;109(4):483-490.

20. García-Noblejas A, Cannata-Ortiz J, Conde E, et al. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO). *Ann Hematol.* 2017;96(8):1323-1330.
21. Wang J, Wei L, Ye J, et al. Autologous hematopoietic stem cell transplantation may improve long-term outcomes in patients with newly diagnosed extranodal natural killer/T-cell lymphoma, nasal type: a retrospective controlled study in a single center. *Int J Hematol.* 2018;107(1):98-104.
22. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in Oncology: B-Cell Lymphomas. v.4.2020
23. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in Oncology: T-Cell Lymphomas. v.1.2020.